메뉴 건너뛰기




Volumn 124, Issue 13, 2005, Pages 497-498

Asthma: Control as therapeutic goal;Asma. El control como meta del tratamiento

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; GLUCOCORTICOID; SALMETEROL;

EID: 18844405501     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13073564     Document Type: Editorial
Times cited : (1)

References (28)
  • 1
    • 85030797973 scopus 로고    scopus 로고
    • Publication N.° 02-3659. Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute
    • Global Initiative for Asthma (Gina). Global strategy for asthma management and prevention: NHLBI/WHO Workshop Report. 2002. Publication N.° 02-3659. Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute; 2002.
    • (2002) Global Strategy for Asthma Management and Prevention: NHLBI/WHO Workshop Report. 2002
  • 5
    • 0034523602 scopus 로고    scopus 로고
    • Clinical management of asthma in 1999: The Asthma Insights and Reality in Europe (AIRE) study
    • Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J. 2000:16:802-7.
    • (2000) Eur Respir J , vol.16 , pp. 802-807
    • Rabe, K.F.1    Vermeire, P.A.2    Soriano, J.B.3    Maier, W.C.4
  • 6
    • 0036849388 scopus 로고    scopus 로고
    • Variability and lack of predictive ability of asthma end-points in clinical trials
    • Zhang J, Yu C, Holgate ST, Reiss TF. Variability and lack of predictive ability of asthma end-points in clinical trials. Eur Respir J. 2002;20: 1102-9.
    • (2002) Eur Respir J , vol.20 , pp. 1102-1109
    • Zhang, J.1    Yu, C.2    Holgate, S.T.3    Reiss, T.F.4
  • 7
    • 0036924083 scopus 로고    scopus 로고
    • How should we quantify asthma control? a proposal
    • Boulet LP, Boulet V, Milot J. How should we quantify asthma control? A proposal. Chest. 2002;122:2217-23.
    • (2002) Chest , vol.122 , pp. 2217-2223
    • Boulet, L.P.1    Boulet, V.2    Milot, J.3
  • 8
    • 0037202790 scopus 로고    scopus 로고
    • Asthma exacerbations and sputum eosinophil counts: A randomised controlled trial
    • Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360:1715-21.
    • (2002) Lancet , vol.360 , pp. 1715-1721
    • Green, R.H.1    Brightling, C.E.2    McKenna, S.3    Hargadon, B.4    Parker, D.5    Bradding, P.6
  • 10
    • 0348225056 scopus 로고    scopus 로고
    • Asthma severity and asthma control: Symptoms, pulmonary function, and inflammatory markers
    • Fuhlbrigge AL. Asthma severity and asthma control: symptoms, pulmonary function, and inflammatory markers. Curr Opin Pulm Med. 2004; 10:1-6.
    • (2004) Curr Opin Pulm Med , vol.10 , pp. 1-6
    • Fuhlbrigge, A.L.1
  • 12
    • 0037313809 scopus 로고    scopus 로고
    • British guideline on the management of asthma
    • BTS/SIGN. British guideline on the management of asthma. Thorax. 2003;58Suppl 1:1-94.
    • (2003) Thorax , vol.58 , Issue.SUPPL. 1 , pp. 1-94
  • 14
    • 0028264310 scopus 로고
    • Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid
    • Alien & Hanburys Limited UK Study Group
    • Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Alien & Hanburys Limited UK Study Group. Lancet. 1994;344:219-24.
    • (1994) Lancet , vol.344 , pp. 219-224
    • Greening, A.P.1    Ind, P.W.2    Northfield, M.3    Shaw, G.4
  • 15
    • 0029880013 scopus 로고    scopus 로고
    • Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids
    • Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996;153:1481-8.
    • (1996) Am J Respir Crit Care Med , vol.153 , pp. 1481-1488
    • Woolcock, A.1    Lundback, B.2    Ringdal, N.3    Jacques, L.A.4
  • 16
    • 1842370350 scopus 로고    scopus 로고
    • Effect of inhaled formoterol and budesonide on exacerbations of asthma
    • Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group
    • Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997;337:1405-11.
    • (1997) N Engl J Med , vol.337 , pp. 1405-1411
    • Pauwels, R.A.1    Lofdahl, C.G.2    Postma, D.S.3    Tattersfield, A.E.4    O'Byrne, P.5    Barnes, P.J.6
  • 18
    • 0034690661 scopus 로고    scopus 로고
    • Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA)
    • Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000;320:1368-73.
    • (2000) BMJ. , vol.320 , pp. 1368-1373
    • Shrewsbury, S.1    Pyke, S.2    Britton, M.3
  • 19
    • 0346688570 scopus 로고    scopus 로고
    • Clinical dose-response relationship of fluticasone propionate in adults with asthma
    • Masoli M, Weatherall M, Holt S, Beasley R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax. 2004;59:16-20.
    • (2004) Thorax , vol.59 , pp. 16-20
    • Masoli, M.1    Weatherall, M.2    Holt, S.3    Beasley, R.4
  • 20
    • 0033542041 scopus 로고    scopus 로고
    • Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis
    • Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med. 1999;159:941-55.
    • (1999) Arch Intern Med , vol.159 , pp. 941-955
    • Lipworth, B.J.1
  • 21
    • 0035806738 scopus 로고    scopus 로고
    • Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: Meta-analysis
    • Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ. 2001;323:253-6.
    • (2001) BMJ , vol.323 , pp. 253-256
    • Holt, S.1    Suder, A.2    Weatherall, M.3    Cheng, S.4    Shirtcliffe, P.5    Beasley, R.6
  • 22
    • 8644233358 scopus 로고    scopus 로고
    • Goals of asthma treatment: How high should we go?
    • Reddel HK. Goals of asthma treatment: how high should we go? Eur Respir J. 2004;24:715-7.
    • (2004) Eur Respir J , vol.24 , pp. 715-717
    • Reddel, H.K.1
  • 23
    • 0032938331 scopus 로고    scopus 로고
    • Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment
    • The AMPUL Study Group
    • Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med. 1999; 159:1043-51.
    • (1999) Am J Respir Crit Care Med , vol.159 , pp. 1043-1051
    • Sont, J.K.1    Willems, L.N.2    Bel, E.H.3    Van Krieken, J.H.4    Vandenbroucke, J.P.5    Sterk, P.J.6
  • 24
    • 0345535838 scopus 로고    scopus 로고
    • Maximal response plateau to methacholine as a reliable index for reducing inhaled budesonide in moderate asthma
    • Prieto L, Gutiérrez V, Morales C. Maximal response plateau to methacholine as a reliable index for reducing inhaled budesonide in moderate asthma. Eur Respir J. 1999;13:1236-44.
    • (1999) Eur Respir J , vol.13 , pp. 1236-1244
    • Prieto, L.1    Gutiérrez, V.2    Morales, C.3
  • 26
    • 1042279583 scopus 로고    scopus 로고
    • Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma
    • Aalbers R, Backer V, Kava TT, Omenaas ER, Sandstrom T, Jorup C, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin. 2004;20:225-40.
    • (2004) Curr Med Res Opin , vol.20 , pp. 225-240
    • Aalbers, R.1    Backer, V.2    Kava, T.T.3    Omenaas, E.R.4    Sandstrom, T.5    Jorup, C.6
  • 28
    • 0032824962 scopus 로고    scopus 로고
    • International variations in asthma treatment compliance: The results of the European Community Respiratory Health Survey (ECRHS)
    • Cerveri I, Locatelli F, Zoia MC, Corsico A, Accordini S, de Marco R. International variations in asthma treatment compliance: the results of the European Community Respiratory Health Survey (ECRHS). Eur Respir J. 1999;14:288-94.
    • (1999) Eur Respir J , vol.14 , pp. 288-294
    • Cerveri, I.1    Locatelli, F.2    Zoia, M.C.3    Corsico, A.4    Accordini, S.5    De Marco, R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.